Solid Biosciences
SLDB
36 hedge funds and large institutions have $85.6M invested in Solid Biosciences in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 5 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
15% more capital invested
Capital invested by funds: $74.8M → $85.6M (+$10.9M)
2.77% more ownership
Funds ownership: 80.6% → 83.37% (+2.8%)
8% less funds holding
Funds holding: 39 → 36 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$2.66M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.11M |
| 3 |
Walleye Capital
New York
|
+$524K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$266K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$1.07M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$804K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$113K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$88.6K |
| 5 |
Renaissance Technologies
New York
|
-$62.4K |
SLDB Hedge Fund Activity: Q2 2023 in Review
36 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q2 2023, worth a combined $85.6M — up 15% from $74.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SLDB and 2 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was Finepoint Capital, adding an estimated $2.66M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $1.07M sold.
- 36 institutional investors held Solid Biosciences (SLDB) as of Q2 2023, down from 39 in Q1 2023.
- Funds reported $85.6M of Solid Biosciences stock for Q2 2023, up 15% quarter-over-quarter.
- 2 funds opened new Solid Biosciences positions in Q2 2023 and 5 closed out, a net change of -3 holders.
- The largest Solid Biosciences buyer in Q2 2023 was Finepoint Capital, an estimated $2.66M added.
- The largest Solid Biosciences seller in Q2 2023 was Pura Vida Investments, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2023.